News & Videos - NEMUS BIOSCIENCE INC

Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will present at the upcoming 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Conference. 9th Annual Glaucoma 360 New Horizons Forum Dr. Brian Murphy...

Company prepares to enter the clinic in 2020 to test NB1111 (THCVHS) in glaucoma Preclinical formulation testing proprietary analog of CBD examining the utility of CBDVHS in the eye, brain, and liver First patents have been issued for CBDVHS in pursuit of a global patent footprint to complement the IP estate for THCVHS LONG BEACH, CA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to...

Long Beach, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will present a corporate overview at the Biotech Showcase 2020 conference to be held on January 13-15, 2020 at the Hilton San Francisco Union Square Hotel in San...

Emerald Health Sciences To Exercise 40.8 Million Warrants, Reducing Outstanding Debt, As Company Changes Name to Embi Pharmaceuticals Punit Dhillon Assumes Board Chairmanship as Dr. Avtar Dhillon Transitions to Board Observer Role LONG BEACH, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced...

Long Beach, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by StemoniX, Inc., using their proprietary microBrain® 3D platform, demonstrated that the proprietary analog of CBD, cannabidiol-valine-hemisuccinate (CBDVHS) was both pharmacologically and therapeutically distinct...

CBDVHS Also Displayed Superior Anti-Inflammatory Activity When Compared to CBD Indicating Potential Use in Diseases of the Retina Unlike CBD, CBDVHS was not Associated with Biomarkers Related to Elevation of Intraocular Pressure (IOP) LONG BEACH, CA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that...

Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced it has entered into a definitive agreement with certain investors for the purchase of 8.0 million shares of common stock at $0.25 per share and 8.0 million warrants to purchase shares of common stock at an exercise price of $0.35 per...

LONG BEACH, CA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will participate in a panel discussion at the Cowen 2nd Annual Boston Cannabis Conference, to be held November 12 -13, 2019, at the InterContinental Hotel in Boston, MA, with 1x1 investor...

Long Beach, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that the University of Mississippi and Eli Labs will present preclinical data evaluating the superiority of its prodrug of tetrahydrocannabinol (THC), NB1111, in lowering intraocular pressure in a multi-dose normotensive rabbit...

LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced data demonstrating the superiority of its advanced formulation of NB1111, the prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate; THCVHS) in lowering intraocular pressure (IOP) in the eye in a validated animal model....

Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced data validating mechanisms of action of its drug candidate, NB1111, a prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate;...

Long Beach, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Glauconix Biosciences, Inc. will be presenting biomarker data in human donor tissue related to the mechanism of action of Emerald’s lead drug candidate, NB1111, a prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate;...

Long Beach, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Brian Murphy, MD, Chief Executive Officer of Emerald Bioscience will present at several upcoming investment and scientific events in September, including Rodman & Renshaw’s 21 st Annual Global Investment Conference, the 2...

Long Beach, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, announced today the appointments of Dennis D. Kim, MD, MBA, as Chief Medical Officer, and Alice Chen as Executive Director, Clinical Operations. “We are pleased to welcome Dennis and Alice to EMBI’s management team,” said Brian Murphy, MD, Chief Executive Officer, EMBI. “Dr. Kim...

Pre-clinical studies of cannabidiol analog to commence Long Beach, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that the company has opened its Australian office. The formation of EMBI Australia Pty Ltd and opening of an Australian office is an important step in meeting regulatory...

Long Beach, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that two posters related to its glaucoma therapeutic candidate, NB1111, will be presented at the 29th Annual Symposium of the International Cannabinoid Research Society. The symposium will be held June 29 - July 4, 2019 at the...

Journal of Ocular Pharmacology and Therapeutics Peer-Reviewed Journal Publishes NB2222 Ocular Bioavailability Data LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that newly published scientific data highlight the superior penetration of EMBI’s drug candidate, NB2222, into ocular tissues in...

LONG BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that Dr. Brian Murphy, Chief Executive Officer and Chief Medical Officer of EMBI, will present a corporate overview at the 9th Annual LD Micro Invitational to be held on June 4-5th, 2019 at the Luxe Sunset Boulevard Hotel in Bel-Air, CA with follow-up...

Licenses Permit Emerald to Develop THC-Prodrug and CBD-Analog for Any Therapeutic Indication by Any Route of Administration for Human and Veterinary Use LONG BEACH, CA, May 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, has signed licenses covering “all fields of use” pertaining to proprietary cannabinoid- derivative molecules...

LONG BEACH, CA , May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, CEO and Chief Medical Officer, will present at the CannaStocks 2019 Q1 Investor Conference on Wednesday, May 15, 2019 at 11 AM EDT at the OTC Markets Group Headquarters, 300 Vesey Street, New York, NY. Dr....